Rituximab: Work on infusions of the B-cell depleting agent has been conducted by Norwegian researchers beginning in 2011 with a small randomized
trial and an open-label, phase 2
study in 2015, both showing clinical responses in ME/CFS. However, a subsequent phase 3, randomized clinical
trial of 151 patients, again diagnosed using the Canadian criteria, was negative.
There are several possible explanations for this, Scheibenbogen noted. For one, the maintenance dose had to be reduced because of a lack of financial support. "This was probably critical. The lower dose was insufficient to adequately deplete B cells."